Mr. Thomas Looby reports

CONAVI MEDICAL ANNOUNCES PEER-REVIEWED CASE REPORT HIGHLIGHTING CLINICAL UTILITY OF HYBRID IVUS-OCT IMAGING, AND PROVIDES UPDATE ON MANAGEMENT TEAM

Conavi Medical Corp. has noted the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging in guiding treatment decisions following stent placement. The case report, titled "Detection of poststent Medial Dissection and White Thrombus Using Hybrid IVUS OCT Imaging may Help Guide Management," was published in Catheterization and Cardiovascular Interventions. The report was authored by Megha Prasad, MD, MS, of Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, together with Khady N. Fall, MD, Jeffrey W. Moses, MD, and Natali Sorajja, MS.

"Hybrid IVUS-OCT imaging provided complementary information that was important in assessing the poststent findings in this case," said Dr. Jeffrey Moses, author and chairman of cardiology at Good Samaritan University Hospital. "The ostial location necessitated IVUS for initial imaging. OCT was then essential in evaluating the dissections after stent placement. The distal medial edge dissection was easily visualized on OCT but less easily discernable on IVUS. IVUS alone may have failed to demonstrate the dissection, which required timely management. Having both modalities available helped guide management and apply treatment guidelines, including the decision to place an additional distal stent while managing the proximal dissection medically."

The report describes the treatment of a 66-year-old patient undergoing percutaneous coronary intervention (PCI) of the right coronary artery. Following stent placement, the clinical team used Conavi's hybrid IVUS-OCT imaging to identify proximal and distal edge dissections, as well as white thrombus. IVUS was used for vessel sizing and plaque assessment, while OCT's higher resolution helped characterize the extent and depth of the dissections. IVUS also helped confirm an irregular protrusion seen on OCT as white thrombus rather than a calcified nodule. The authors noted that without identification of the thrombus, in-stent thrombosis could have led to further vessel occlusion and a potentially catastrophic event. The authors noted that this combined evaluation may be important in helping prevent acute vessel closure, major adverse cardiovascular events and target revascularization.

"This case provides a very clear example of why combining IVUS and OCT can matter clinically," said Thomas Looby, president and chief executive officer of Conavi Medical. "The two modalities provided complementary information that helped physicians identify and assess poststent complications and determine when an additional stent was warranted and when medical management was appropriate. Together with other recent case reports, this publication adds to the clinical evidence supporting the potential value of hybrid imaging in complex coronary procedures."

The publication follows other previously published case reports highlighting the use of Conavi's hybrid IVUS-OCT technology in complex coronary interventions. In July, 2026, a Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) case report highlighted the use of hybrid imaging in the contrast-sparing management of eruptive calcified nodules in a patient with impaired renal function. In July, 2025, another JSCAI case report highlighted the use of hybrid imaging to identify plaque rupture and guide ostial stent placement in a complex coronary procedure. Together, these publications add to a growing body of clinical evidence highlighting the potential utility of hybrid IVUS-OCT imaging across a range of complex coronary procedures.

Innovation leadership update

Amandeep Thind, chief technology officer and co-founder, will assume leadership of Conavi's research and development efforts. A co-inventor of the company's hybrid IVUS-OCT technology, Mr. Thind brings deep technical expertise and continuity as Conavi advances commercialization following the system's recent Food and Drug Administration clearance.

Sumeet Dham, vice-president of research and development, will be departing the company. Conavi thanks Mr. Dham for his years of leadership and valuable contributions to its technology and key development milestones, and wishes him continued success.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration.

We seek Safe Harbor.